Oxaliplatin combined with 5-fluorouracil and methotrexate in advanced colorectal cancer

Autor:	Zampino, M. G., Lorizzo, K., Rocca, A., Locatelli, M., Zorzino, L., Manzoni, S., Mazzetta, C., nicola fazio, Biffi, R., Braud, F.
Rok vydání:	2006
Předmět:	Adult Male Vascular Endothelial Growth Factor A Organoplatinum Compounds Middle Aged Drug Administration Schedule Oxaliplatin Methotrexate Antineoplastic Combined Chemotherapy Protocols Humans Female Fluorouracil Colorectal Neoplasms Infusions Intravenous Aged
Zdroj:	Scopus-Elsevier Europe PubMed Central
ISSN:	0250-7005
Popis:	A promising regimen including 5-Fluorouracil, methotrexate and oxaliplatin is reported.Patients with untreated measurable metastatic disease received bolus 5-Fluorouracil (600 mg/m2) on days 2 and 16, modulated by methotrexate (200 mg/m2) 24 h earlier, alternated with 4 weeks of continuous infusion of 5-Fluorouracil (200 mg/m2/daily) plus oxaliplatin (130 mg/m2) on days 29 and 56, followed by 2 weeks of rest. Serum vascular endothelial growth factor (VEGF) was analyzed at baseline and before every cycle.Fifty-eight patients were enrolled. Objective remissions were reported in 45.6% (95% CI=34.3%, 57.3%). The median progression-free survival was 7.8 months and the median overall survival was 19.4 months. No grade 4 toxicity was reported, except for one case of diarrhea. The serum VEGF evaluated in 23 patients showed a decreasing trend during therapy.The regimen was active, well tolerated and may be a possible option in patients not suitable for radical surgery.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::ae5afcb4c0fe76df9fffafc2eccebee9 https://pubmed.ncbi.nlm.nih.gov/16821627 Zobrazit plný text záznamu